Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] stock went on a downward path that fall over -5.81% on Wednesday, amounting to a one-week price decrease of less than -6.90%.
Over the last 12 months, MRVI stock dropped by -68.44%. The one-year Maravai LifeSciences Holdings Inc stock forecast points to a potential upside of 69.96. The average equity rating for MRVI stock is currently 2.17, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $613.64 million, with 141.59 million shares outstanding and 117.88 million shares in the current float. Compared to the average trading volume of 2.86M shares, MRVI stock reached a trading volume of 5278973 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Maravai LifeSciences Holdings Inc [MRVI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRVI shares is $8.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRVI stock is a recommendation set at 2.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Maravai LifeSciences Holdings Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 26, 2025. While these analysts kept the previous recommendation, Guggenheim raised their target price to Neutral. The new note on the price target was released on December 19, 2024, representing the official price target for Maravai LifeSciences Holdings Inc stock. Previously, the target price had yet another raise to $4.25, while Goldman analysts kept a Sell rating on MRVI stock.
The Average True Range (ATR) for Maravai LifeSciences Holdings Inc is set at 0.30, with the Price to Sales ratio for MRVI stock in the period of the last 12 months amounting to 2.22. The Price to Book ratio for the last quarter was 1.00, with the Price to Cash per share for the same quarter was set at 2.29.
MRVI Stock Performance Analysis:
Maravai LifeSciences Holdings Inc [MRVI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.90. With this latest performance, MRVI shares dropped by -40.73% in over the last four-week period, additionally sinking by -73.41% over the last 6 months – not to mention a drop of -68.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRVI stock in for the last two-week period is set at 29.49, with the RSI for the last a single of trading hit 29.54, and the three-weeks RSI is set at 30.87 for Maravai LifeSciences Holdings Inc [MRVI]. The present Moving Average for the last 50 days of trading for this stock 4.15, while it was recorded at 2.50 for the last single week of trading, and 6.69 for the last 200 days.
Insight into Maravai LifeSciences Holdings Inc Fundamentals:
Maravai LifeSciences Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.94 and a Current Ratio set at 10.74.
Maravai LifeSciences Holdings Inc [MRVI] Institutonal Ownership Details
There are presently around $99.70%, or 100.91%% of MRVI stock, in the hands of institutional investors. The top three institutional holders of MRVI stocks are: GTCR LLC with ownership of 20.15 million shares, which is approximately 14.8334%. 12 WEST CAPITAL MANAGEMENT LP, holding 13.21 million shares of the stock with an approximate value of $$94.59 million in MRVI stocks shares; and 12 WEST CAPITAL MANAGEMENT LP, currently with $$76.96 million in MRVI stock with ownership which is approximately 8.1224%.
